William Parfet - Stryker Non-Executive Independent Chairman of the Board

SYK Stock  EUR 329.00  4.90  1.51%   

Chairman

Mr. William U. Parfet is Lead Independent Director of Stryker Corp since 2014.
Age 68
Tenure 10 years
Phone269 385 2600
Webhttps://www.stryker.com
Parfet recently retired as Chairman and Chief Executive Officer of MPI Research, Inc., a global preclinical research organization. He had served as Chairman and CEO of MPI since 1999. He is a director of Monsanto Company, a provider of agricultural products that improve farm productivity, and Taubman Centers, Inc., a real estate development company. From 1993 to 1996, Mr. Parfet served as the president and CEO of RichardAllan Medical, a worldwide manufacturer of surgical products. Prior to that, he had a 30year career with the Upjohn Company as both an executive and member of the Board of Directors. He also previously served as a trustee of the Financial Accounting Foundation, the group that oversees the Financial Accounting Standards Board

Stryker Management Efficiency

The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 11.86 B in total debt with debt to equity ratio (D/E) of 74.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Stryker has a current ratio of 2.03, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 36000 people. Stryker (SYK) is traded on Frankfurt Exchange in Germany and employs 51,000 people.

Management Performance

Stryker Leadership Team

Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director
Fink, Vice President Global Human Resources
Sherilyn McCoy, Independent Director
Robert Cohen, CTO Replacement
Ronda Stryker, Independent Director
Curtis Hall, Chief Legal Officer
Spencer Stiles, Group Spine
Andrew Pierce, Group Neurotechnology
William Berry, Principal Accounting Officer, Vice President Corporate Controller
Allan Golston, Independent Director
Katherine Owen, Vice President - Strategy and Investor Relations
Graham Mclean, President Asia-Pacific
Louise Francesconi, Independent Director
Kevin Lobo, President CEO, Director
Jason Beach, VP Relations
Roch Doliveux, Independent Director
David Floyd, Group President - Orthopaedics
William Jellison, CFO, Vice President
Yin Becker, Vice President of Communication and Public Affairs
Timothy Scannell, Group President - MedSurg and Neurotechnology
William Parfet, Non-Executive Independent Chairman of the Board
Robert Fletcher, Vice President Chief Legal Officer
Dean Bergy, Vice President Corporate Secretary
Rajeev Suri, Independent Director
Alan Douville, Chief VP
Glenn Boehnlein, CFO, Vice President
Viju Menon, Group President - Global Quality and Business Operations
Lonny Carpenter, Group President - Global Quality and Operations
Bijoy Sagar, CIO, Vice President
Mary Brainerd, Director
Srikant Datar, Independent Director
Michael Hutchinson, General Counsel
Bronwen Taylor, Vice President - Compliance and Risk Management
Howard Cox, Independent Director
Steven Benscoter, Vice President - Human Resources
Kathryn Fink, Chief Human Resource Officer, Vice President
Scott Bruder, Vice President Chief Medical and Scientific Officer

Stryker Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Stryker Stock analysis

When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.